Jonathan C. Fox

BridgeBio (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index1.9kcitations46works21.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyloidosis: Diagnosis, Treatment, Outcomes(23), Parathyroid Disorders and Treatments(11), Coagulation, Bradykinin, Polyphosphates, and Angioedema(7), Chronic Obstructive Pulmonary Disease (COPD) Research(6), Cellular transport and secretion(5)

Publications46 total

Abstract 4368295: Acoramidis Reduces All-Cause Mortality and First Cardiovascular Hospitalization in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results From the ATTRibute-CM Study
Circulation·2025
Abstract 4368185: Serum Transthyretin Levels at Day 28 are Associated with Cardiovascular Outcomes: Insights From the ATTRibute-CM Study
Circulation·2025
Abstract 4363872: Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients With Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Circulation·2025
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM
Journal of the American College of Cardiology·2025· 3 citedOpen Access
Acoramidis Improves Serum Transthyretin Levels in Patients With Wild-type or Variant Transthyretin Amyloid Cardiomyopathy - Results From ATTRibute-CM
Journal of Nuclear Cardiology·2025
Acoramidis Has a Beneficial Effect Compared With Placebo on Change From Baseline in NAC ATTR Stage at Month 30 in Patients With ATTR-CM: Results From the ATTRibute-CM Study
Journal of Nuclear Cardiology·2025
Acoramidis-Mediated Improvement in NT-proBNP at Month 30 Compared With Placebo in Patients With ATTR-CM: Results From the ATTRibute-CM Study
Journal of Nuclear Cardiology·2025
ATTribute-CM Study: Scintigraphic Diagnosis and Long-Term Cardiovascular Outcome Benefits of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Journal of Nuclear Cardiology·2025
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy
Journal of the American College of Cardiology·2025· 21 citedOpen Access
ACORAMIDIS IMPROVES NYHA CLASS AT MONTH 30 VERSUS PLACEBO IN PATIENTS WITH ATTRCM: RESULTS FROM THE ATTRIBUTE-CM STUDY
Journal of the American College of Cardiology·2025Open Access
ACORAMIDIS-MEDIATED EARLY INCREASE IN SERUM TRANSTHYRETIN LEVEL REDUCES CARDIOVASCULAR-RELATED HOSPITALIZATIONS AND MORTALITY: INSIGHTS FROM THE ATTRIBUTE-CM STUDY
Journal of the American College of Cardiology·2025Open Access
PRIMARY ENDPOINT EFFICACY RESULTS IN THE ATTRIBUTE-CM STUDY: PRE-SPECIFIED SENSITIVITY ANALYSES ADDRESSED TAFAMIDIS USE
Journal of the American College of Cardiology·2025· 1 citedOpen Access
ROBUSTNESS OF PRIMARY ENDPOINT EFFICACY RESULTS WITH ACORAMIDIS IN ATTR-CM IN THE ATTRIBUTE-CM STUDY: PRE-SPECIFIED NT-PROBNP SENSITIVITY ANALYSES
Journal of the American College of Cardiology·2025Open Access
ACORAMIDIS IMPROVES SERUM TTR LEVELS IN PATIENTS WITH WILD-TYPE OR VARIANT TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Journal of the American College of Cardiology·2025· 1 citedOpen Access
IN PARTICIPANTS TREATED WITH ACORAMIDIS, ADDITION OF CONCOMITANT TAFAMIDIS DID NOT FURTHER INCREASE SERUM TTR LEVELS
Journal of the American College of Cardiology·2025Open Access
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
Journal of the American College of Cardiology·2025· 30 citedOpen Access
ACORAMIDIS IMPROVES CLINICAL OUTCOMES IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A POST HOC RECURRENT EVENT ANALYSIS OF ATTRIBUTE-CM STUDY
Journal of Cardiac Failure·2025
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial
Circulation·2024· 41 citedOpen Access
Abstract 4147141: Relationship Between CVH and Survival in the Acoramidis Treated Participants Within ATTRibute-CM
Circulation·2024
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy
Circulation Heart Failure·2024· 15 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Daniel P. Judge(19), Uma Sinha(18), Julian D. Gillmore(16), Jean‐François Tamby(15), Mathew S. Maurer(13), Suresh Siddhanti(13), Francesco Cappelli(10), Martha Grogan(10), Ahmad Masri(10), Kevin Alexander(10), Adam Castaño(10), Laura Obici(8), Pablo García‐Pavía(7), Steen Hvitfeldt Poulsen(7), Prem Soman(7), Amrut V. Ambardekar(7), Justin L. Grodin(7), Nitasha Sarswat(7), Jing Du(7), José Nativi-Nicolau(6)